Search results
Showing 1951 to 2000 of 3765 results for treatment
NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .
Low-energy contact X-ray brachytherapy for rectal cancer (IPG809)
Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.
View recommendations for IPG809Show all sections
Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures (IPG623)
Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures in adults. This involves using an ultrasound probe on the skin at the site of the fracture.
View recommendations for IPG623Show all sections
Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.
View recommendations for IPG715Show all sections
Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension (IPG801)
Evidence-based recommendations on alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. This involves putting alcohol into the wall of a renal artery to destroy renal nerves.
View recommendations for IPG801Show all sections
Stroke and ischaemic attack: anti-platelet or anticoagulation (IND133)
This indicator covers the percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM94.
This indicator covers the percentage of patients with diabetes who have a record of an albumin creatinine ratio (ACR) test in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of women who have had gestational diabetes, diagnosed more than 12 months ago, who have had an HbA1c test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM151
Lipid disorders: FH assessment and diagnosis (new readings) (IND261)
This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245
Atrial fibrillation: DOACs and Vitamin K antagonists (IND247)
This indicator covers the percentage of patients with atrial fibrillation and a last recorded CHA2DS2-VASc score of 2 or more who are currently prescribed a direct-acting oral anticoagulant (DOAC) if eligible, or a vitamin K antagonist if not eligible for a DOAC or a DOAC is declined, clinically unsuitable or not indicated. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM231
Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain (IPG234)
Evidence-based recommendations on laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain. This involves the destruction of a small segment of ligament that carries nerve fibres within the pelvis.
View recommendations for IPG234Show all sections
Sections for IPG234
Transcranial direct current stimulation (tDCS) for depression (IPG530)
Evidence-based recommendations on transcranial direct current stimulation (tDCS) for depression. This involves electrical stimulation of the brain by applying a weak direct current to the scalp.
Discontinued Reference number: GID-TA10628
Recommendation ID NG69/1 Question Psychological treatments for binge eating disorder: - Compare the clinical and cost effectiveness of
at increased risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how...
Evidence-based recommendations on photodynamic therapy for bile duct cancer. This involves injecting a photosensitising agent into the body that is then activated by a small laser to destroy cancer cells and shrink the blockage.
View recommendations for IPG134Show all sections
Sections for IPG134
Extracorporeal shockwave therapy for refractory tennis elbow (IPG313)
Evidence-based recommendations on extracorporeal shockwave therapy for refractory tennis elbow. This involves using a machine to deliver sound waves to the painful area to stimulate healing.
View recommendations for IPG313Show all sections
Sections for IPG313
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance
This indicator covers the proportion of babies with a screen positive newborn hip result who attend for ultrasound scan of the hips within the designated timescale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG96
Myocardial infarction: medication for MI more than 12 months ago (IND126)
This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80
Smoking: smoking status of people with bipolar, schizophrenia and other psychoses (IND154)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM124
Smoking: smoking status of people with long-term conditions (IND156)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126
This indicator covers the percentage of patients (aged 65 years and over) with moderate or severe frailty who have been asked whether they have had a fall, about the total number of falls and about the type of falls, in the last 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM187
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.
This indicator covers the percentage of women eligible for cervical screening and aged 25 to 64 years at end of the period reported whose notes record that an adequate cervical screening test has been performed in the previous 5.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Phototherapeutic laser keratectomy for corneal surface irregularities (IPG358)
Evidence-based recommendations on phototherapeutic laser keratectomy for corneal surface irregularities. This involves using a laser to remove layers of the cornea in order to produce a smooth, even surface with the aim of improving vision.
View recommendations for IPG358Show all sections
Sections for IPG358
This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.
Show all sections
Sections for NG12
Partial replacement of the meniscus of the knee using a biodegradable scaffold (IPG430)
Evidence-based recommendations on partial replacement of the meniscus of the knee using a biodegradable scaffold. This involves placing a biodegradable implant into the meniscus to support regrowth and repair of the damage.
View recommendations for IPG430Show all sections
Sections for IPG430
In development Reference number: GID-TA11400 Expected publication date: TBC
Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (IPG439)
Evidence-based recommendations on deep dermal injection of non absorbable gel polymer for HIV-related facial lipoatrophy. This involves injecting the gel polymer under the skin to restore the shape and volume of the areas where fat has been lost.
View recommendations for IPG439Show all sections
Sections for IPG439
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)
Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.
View recommendations for TA304Show all sections
Pharyngeal electrical stimulation for neurogenic dysphagia (IPG781)
Evidence-based recommendations on pharyngeal electrical stimulation for neurogenic dysphagia. This involves passing a catheter through the nose and into the throat where it is used to deliver small amounts of electrical current. The current travels from the throat to the brain and stimulates the areas involved in swallowing.
View recommendations for IPG781Show all sections
Percutaneous intradiscal laser ablation in the lumbar spine (IPG357)
Evidence-based recommendations on percutaneous intradiscal laser ablation in the lumbar spine. This involves using a laser to destroy part of the disc, with the aim of shrinking it.
View recommendations for IPG357Show all sections
Sections for IPG357
Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain.
Melatonin for treating sleep disorders in adults who are blind (ES38)
Summary of the evidence on melatonin for treating sleep disorders in adults who are blind
Transmyocardial laser revascularisation for refractory angina pectoris (IPG301)
Evidence-based recommendations on transmyocardial laser revascularisation for refractory angina pectoris. This involves open heart surgery to drill holes on the heart muscle using a laser beam.
View recommendations for IPG301Show all sections
Sections for IPG301
Discontinued Reference number: GID-TA11026
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
Transcranial magnetic stimulation for obsessive-compulsive disorder (IPG676)
Evidence-based recommendations on transcranial magnetic stimulation for obsessive-compulsive disorder in adults. This involves pulsing electromagnetic energy through the skull to stimulate the brain.
View recommendations for IPG676Show all sections
Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis (IPG681)
Evidence-based recommendations on pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in adults. This involves spraying the inside of the peritoneal cavity with chemotherapy.
View recommendations for IPG681Show all sections
Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma (IPG692)
Evidence-based recommendations on short-pulse transscleral cyclophotocoagulation for glaucoma. This involves using repeated short pulses of laser energy to destroy some of the cells in the eye that produce fluid.
View recommendations for IPG692Show all sections
Evidence-based recommendations on retrobulbar irradiation for thyroid eye disease. This involves using radiation to target the tissue behind the eyeball and reduce inflammation.
View recommendations for IPG148Show all sections
Sections for IPG148
Evidence-based recommendations on percutaneous endoscopic colostomy. This involves placing a plastic tube in the bowel that runs back through a small opening in the abdomen to allow waste to pass through to a drainage bag worn outside the body.
View recommendations for IPG161Show all sections
Sections for IPG161
NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .
Evidence-based recommendations on selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma in adults. This involves injecting tiny radioactive ‘beads’ into blood vessels that supply the liver, where they become trapped and release radiation directly into the cancer cells.
View recommendations for IPG630Show all sections
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382)
Evidence-based recommendations on deep brain stimulation for refractory chronic pain syndromes (excluding headache). This involves stimulating a precise area of the brain using an electrode to treat the chronic pain.
View recommendations for IPG382Show all sections
Sections for IPG382
Endopyelotomy for pelviureteric junction obstruction (IPG325)
Evidence-based recommendations on endopyelotomy for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting small instruments either up through the urinary tract or down through the skin and into the kidney.
View recommendations for IPG325Show all sections
Sections for IPG325
Coil embolisation of unruptured intracranial aneurysms (IPG105)
Evidence-based recommendations on coil embolisation of unruptured intracranial aneurysms. This involves placing coils inside the aneurysm using a thin tube to make the blood clot so it is less likely to burst.
View recommendations for IPG105Show all sections
Sections for IPG105
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional